Sanofi will limit its price increases in the US

The CEO of Sanofi pharmaceutical group, Olivier Brandicourt, announced Tuesday the commitment of the laboratory to limit the increase in its prices in the United States to a level less than or equal to the inflation of health costs, 5,4% expected in 2017.

Mr. Brandicourt stated, in a statement published on the Group's website, that Sanofi "is committed to transparency with regard to the elements it takes into consideration when setting the price of its medicines", making public principles for the development of its prices in the United States.

These principles are based in particular on an "overall assessment of the value" of the drug, taking into account the comparable therapeutic options available, and on "affordability for patients".

Each player in the pharmaceutical chain has "a role to play in ensuring the sustainability of the system" and "our sector must participate in the long-term balance of resources," says Brandicourt.

"For this reason, the price increases we will be practicing in the United States will be less than or equal to the standard inflation-independent index of health care costs," based on the projected growth in national health care spending. health, says the boss of Sanofi.

For 2017, this will limit Sanofi's price increase to "5,4%, whatever the product considered," he says.

Sanofi adds that given the size of its portfolio, it may have to decide "for good reasons" increases above the benchmark. The group will then make public the information that motivates this decision.

Sanofi also commits to "divulge, starting today, the figures of aggregate increases, gross and net, the price of (its) drugs in the United States", starting from 2016.

The group specifies that in 2016, for its entire portfolio in the United States, the average increase in the list price was 4% compared to 2015, while the average net prices fell by 2,1%.

US President Donald Trump launched an offensive in March against soaring drug prices in the United States, saying he was working on a new system with "competition in the pharmaceutical industry."

"The price for Americans will go down," he had tweeted.